Provided by Tiger Trade Technology Pte. Ltd.

Dare Bioscience

0.7506
-0.0701-8.54%
Post-market: 0.7405-0.0101-1.35%19:14 EDT
Volume:953.73K
Turnover:736.52K
Market Cap:14.54M
PE:-0.96
High:0.8472
Open:0.8332
Low:0.7400
Close:0.8207
52wk High:3.78
52wk Low:0.7400
Shares:19.38M
Float Shares:18.13M
Volume Ratio:1.82
T/O Rate:5.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7779
EPS(LYR):-1.1986
ROE:-2543.13%
ROA:-39.29%
PB:-25.93
PE(LYR):-0.63

Loading ...

Dare Bioscience - Files for Resale of up to 8,934,345 Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
2 hours ago

Daré Bioscience Posts Phase 1 Data Showing Topical Sildenafil Cream Well Tolerated in Postmenopausal Women

Reuters
·
Yesterday

Daré Bio CEO Flags Ovaprene Interim Phase 3 Results as Potential Catalyst in Investor Interview

Reuters
·
Aug 25

Press Release: Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment

Dow Jones
·
Aug 25

Daré Bioscience DARE-HPV Program Advances with Non-Dilutive US Government Funding

Reuters
·
Aug 18

DarÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 over 50: Innovation” List

THOMSON REUTERS
·
Aug 18

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

GlobeNewswire
·
Aug 18

Daré Bioscience Prices USD 6 Million Registered Direct Offering at USD 1.37 Per Share

Reuters
·
Aug 17

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)

TIPRANKS
·
Aug 16

Dare Bioscience Prices $6 Million Registered Direct Offering; Shares Fall

MT Newswires Live
·
Aug 15

Daré Bioscience to Issue Series A, Series B Warrants in Private Placement for up to 8,759,162 Shares

Reuters
·
Aug 15

NASDAQ Trade Halt Volatility Trading Pause at 12:45 Pm

Reuters
·
Aug 15

DarÉ Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

THOMSON REUTERS
·
Aug 15

Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire
·
Aug 15

VistaGen Q1 Revenue Rises on Licensing Agreement Expiration

Reuters
·
Aug 14

Dare Bioscience Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Dare Bioscience, Inc. Q2 EPS USD -0.2

THOMSON REUTERS
·
Aug 14

Dare Bioscience Q2 EPS $(0.20) Beats $(0.24) Estimate, Sales $187.546K Beat $2.000K Estimate

Benzinga Earnings
·
Aug 14

Daré Bioscience Q2 FY26 Net Loss Narrows to $2.98 Million; Revenue Rises to $187,546

Reuters
·
Aug 14

DarÉ Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

THOMSON REUTERS
·
Aug 14